Company Overview and News

20
Queensland Mining Awards 2018 finalists announced

9h australianmining.com.au
The Queensland Mining Awards has announced its cohort of finalists, which range from small, locally owned companies such as Mackay-based QCCS and HMA Wear Solutions, to large contractors such as Downer, McLanahan and Wolff and producers Rio Tinto.
RTPPF RIO RIO AAUKF RIO RTNTF AAL NGLOY

32
Miners BHP Billiton and Anglo American advance new projects

2018-06-14 telegraph.co.uk
Two of the world’s biggest mining companies have signalled they will push ahead with long-awaited expansion projects, tapping new supply of iron ore and copper.
BLT BHP AAUKF BHPBF BBL AAL BHP BHPLF NGLOY

4
How Dreadful Could A U.S. Trade War Be?

2018-06-12 seekingalpha
The effects of steel and aluminum tariffs are negative but modest, as the targeted categories account for just 2% of total US imports.
AAUKF AAL NGLOY

32
'Tip of the iceberg': Coal miner's death after silicosis diagnosis a warning on dangerous dust levels

2018-06-07 abc.net.au
Queensland miner Tyrone Buckton never spent a day underground but last week died after being diagnosed with silicosis.
BLT BHP AAUKF BHPBF BBL AAL BHP BHPLF NGLOY

6
Orca Gold Inc. Announces Annual General Meeting Results and New Chief Financial Officer

2018-06-01 globenewswire
VANCOUVER, British Columbia, June 01, 2018 (GLOBE NEWSWIRE) -- Orca Gold Inc. (TSXV:ORG) (“Orca” or the “Company”) is pleased to announce that the nominees set forth in the Company’s management information circular dated April 26, 2018, L. Simon Jackson, Richard Clark, Hugh Stuart, Alexander Davidson, Robert Chase, David Field and Derek White were elected as directors of the Company at the Annual General Meeting held on May 30, 2018 (the “Meeting”).
LUC LUCRF AAUKF AAL CANWF ORG NGLOY

4
From Chopping Block to ‘Core,’ Anglo Fires Up Met-Coal Engine - Bloomberg

2018-05-31 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AAUKF AAL NGLOY

46
Would Wider-Than-Expected Discount To Benchmark Price Make Fortescue More Competitive?

2018-05-31 seekingalpha
Cost performance in the first half of 2018 protected margins against a backdrop of lower price realizations.
RIO RIO BLT BHP RIO AAUKF BHPBF BBL AAL BHP BHPLF NGLOY

5
De Beers Group plans sales laboratory-grown diamonds to US consumers

2018-05-30 cnbc
Want to buy a lab-grown diamond? The world's biggest diamond mining company is betting lower prices will lure U.S. shoppers to man-made stones.
AAUKF AAL NILE NGLOY

48
Why These Copper Miners Lowered Their Production Guidance

2018-05-29 marketrealist
Previously in this series, we’ve looked at major copper producers’ first-quarter production data. In this article, we’ll look at the 2018 production guidance provided by leading copper miners. We’ll be focusing on companies that changed their guidance this year.
RIO BLT RIO BHPBF SCCO AAL RTPPF BHP AAUKF RIO RTNTF BBL BHP BHPLF NGLOY

49
Anglo American Seriously Rethinking Iron Price Returns

2018-05-29 seekingalpha
Anglo American was hit hard during the commodity prices crash of 2015 and 2016 but was able to generate positive free cash flow in 2017.
RIO RIO BLT NMDC BHPBF AAL GOLD KIROY RTPPF KUMBF BHP RIO AAUKF BBL RTNTF BHP BHPLF NGLOY

4
De Beers to sell jewellery made from synthetic diamonds for first time

2018-05-29 telegraph.co.uk
For years diamond giant De Beers championed the purity and rareness of natural gemstones, warning of the dangers posed by lab-grown products that seek to pass themselves off as the real thing. Now the company has decided that if synthetics can’t be beaten, it must join them - by announcing a new venture that will sell artificial diamond jewellery.
AAUKF AAL NGLOY

14
Anil Agarwal wants to build Vedanta into giant producer of commodities to rival majors

2018-05-27 livemint
London: Billionaire industrialist Anil Agarwal plans to leave behind a legacy: an Indian resources group to rival the world’s biggest.
AULGF VED AAUKF AU HNDZY AAL AGG NGLOY VEDL 500188 HINDZINC

48
Sterlite protests land a blow to Vedanta boss Anil Agarwal’s ambitions

2018-05-25 livemint
New Delhi: Indian billionaire Anil Agarwal often talks about his dream to turn his London-listed company Vedanta Resources Plc into a global resources giant. He has already bought stakes in big mining companies, such as Anglo American Plc, and says he plans to spend at least $1 billion on investments in Africa.
RIO BLT RIO BHPBF AAL RTPPF VED BHP AAUKF RIO RTNTF BBL BHP BHPLF NGLOY

48
Deadly protests land a blow to Indian resources magnate Agarwal's ambitions

2018-05-25 channelnewsasia
Indian billionaire Anil Agarwal often talks about his dream to turn his London-listed company Vedanta Resources into a global resources giant. He has already bought stakes in big mining companies, such as Anglo American Plc, and says he plans to spend at least US$1 billion on investments in Africa.
RIO BLT RIO BHPBF AAL RTPPF VED BHP AAUKF RIO RTNTF BBL BHP BHPLF NGLOY

32
Colombia coal output falls 11.7 pct in Q1 to 19.6 mln tonnes

2018-05-23 reuters
BOGOTA, May 23 (Reuters) - Colombia, the world’s fifth-largest exporter of coal, produced 19.6 million tonnes in the first quarter, down 11.7 percent from output the year before, the Energy and Mining Ministry said in a statement on Wednesday.
BLT BHP AAUKF BHPBF BBL AAL BHP BHPLF NGLOY

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 00B1XZS82